As 2024 draws to a close, we want to take a moment to reflect on the progress we’ve made together. Your support—whether through donations, fundraising, or sharing our mission—has been invaluable in our quest to understand and conquer ME/CFS and Long COVID.
In Case You Missed It: 2024 Publications Overview
- Melbourne ME/CFS Collaboration: In vitro B cell experiments explore the role of CD24, CD38, and energy metabolism in ME/CFS
- Collaborative Center at Uppsala: Analysis of tryptophan metabolites and related compounds in human and murine tissue: development and validation of a quantitative and semi-quantitative method using high resolution mass spectrometry
- Melbourne ME/CFS Collaboration: Unravelling Shared Mechanisms: Insights from Recent ME/CFS Research to Illuminate Long COVID Pathologies
- Collaborative Center at Stanford: Longitudinal Cytokine and Multi-modal Health Data of an Extremely Severe ME/CFS Patient with HSD Reveals Insights into Immunopathology, and Disease Severity
- Collaborative Center at Uppsala: Untargeted Metabolomics and Quantitative Analysis of Tryptophan Metabolites in Myalgic Encephalomyelitis Patients and Healthy Volunteers: A Comparative Study Using High-Resolution Mass Spectrometry
- Melbourne ME/CFS Collaboration: Discriminating ME/CFS and Comorbid Conditions Using NMR Metabolomics in UK Biobank
In Case You Missed It: 2024 Preprints
- Computational Research Center: Systems Modeling Reveals Shared Metabolic Dysregulation and Novel Therapeutic Treatments in ME/CFS and Long COVID
- Computational Research Center & Collaborative Center at Stanford: A Network Medicine Approach to Investigating ME/CFS Pathogenesis in Severely Ill Patients: A Pilot Study
- Computational Research Center: Patient-Reported Treatment Outcomes in ME/CFS and Long COVID
Your year-end gift will ensure that this momentum continues as we enter 2025. With each gift, we take another step closer to a world where ME/CFS and Long COVID are fully understood, effectively treated, and ultimately cured.
Donate your appreciated stock directly to OMF and you can receive an immediate income-tax deduction for the fair market value of the securities on the date of transfer (even if you originally paid much less for them).